After 20 Years, Compugen Finally Finds Its Mojo

CEO Dr. Anat Cohen-Dayag is confident that, after signing a licensing agreement with Bayer of Germany, Compugen has finally emerged from the doldrums.

The shares of Compugen, a genomics-based drug and diagnostic discovery company, soared by more than 40% on the Tel Aviv Stock Exchange on Monday last week. That dramatic recovery, which raised Compugen’s total share value to more than NIS 1 billion, followed the company’s announcement that it had signed a licensing and collaboration agreement...